Glenmark becomes the First Pharmaceutical Company to launch a Combination Drug for Type 2 Diabetes in India
Glenmark Pharmaceuticals Limited, a worldwide pharmaceutical business focused on innovation, has launched a unique fixed-dose combination (FDC) of Teneligliptin, a commonly used DPP4 inhibitor, and Pioglitazone. For people with uncontrolled Type 2 diabetes, this is the only DPP4 and Glitazone combo brand available in India. Glenmark has launched the Zita Plus Pio FDC, which comprises Teneligliptin (20 mg) and Pioglitazone (15 mg) and is used once a day.
Glenmark is the first firm in India to offer the DCGI-approved novel FDC combination teneligliptin + pioglitazone (Drug Controller General of India). Patients who require treatment with Teneliglitptin and Pioglitazone (as separate medications) to improve glycemic control and reduce Insulin Resistance will benefit from this fixed-dose combination. Cell dysfunction and insulin resistance are common problems in type 2 diabetes.
“Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients,”Alok Malik, Group Vice President & Head, India Formulations, Glenmark Pharmaceuticals, said.
The efficacy of Glenmark’s FDC of Teneligliptin + Pioglitazone in addressing these two most critical pathophysiologies makes the FDC more effective in managing uncontrolled Type 2 diabetes. Teneligliptin + Pioglitazone will work together to give a synergistic strategy, with Teneligliptin improving cell sensitivity and Pioglitazone successfully reducing insulin resistance. Glenmark’s contribution to the treatment of diabetes Glenmark revolutionized the diabetes market in 2015 when it launched Teneligliptin, a DPP4 inhibitor, in India, followed by an FDC of Teneligliptin + Metformin. Glenmark has a long history of success and innovation spanning more than four decades. In 2021, it will offer an FDC of Teneligliptin + Remogliflozin, continuing its first-in-India legacy.
India is renowned as the world’s diabetes capital. According to the International Diabetes Federation (IDF), India currently has roughly 74 million adults with diabetes, with that number anticipated to rise to 125 million (almost 70% increase) by 2045i. 77 percent of these patients have uncontrolled diabetes.
Contact us with your feedback and suggestions.